The latest price target for CervoMed (NASDAQ:CRVO) was reported by HC Wainwright & Co. on July 9, 2026. The analyst firm set a price target for $25.00 expecting CRVO to rise to within 12 months (a possible 586.96% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for CervoMed (NASDAQ:CRVO) was provided by HC Wainwright & Co., and CervoMed reiterated their buy rating.

The last upgrade for CervoMed Inc happened on November 5, 2025 when HC Wainwright & Co. raised their price target to $25. HC Wainwright & Co. previously had a neutral for CervoMed Inc.

The last downgrade for CervoMed Inc happened on December 17, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for CervoMed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CervoMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CervoMed was filed on July 9, 2026 so you should expect the next rating to be made available sometime around July 9, 2027.

While ratings are subjective and will change, the latest CervoMed (CRVO) rating was a reiterated with a price target of $25.00 to $25.00. The current price CervoMed (CRVO) is trading at is $3.64, which is out of the analyst’s predicted range.